Alliance for Pandemic Preparedness

November 16, 2020

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study



Keywords (Tags):

[Press release, not peer-reviewed] The COVID-19 vaccine candidate (mRNA-1273) from Moderna demonstrated 94.5% efficacy in Phase 3 of the COVE study, which is evaluating the effect of the vaccine on disease prevention and severity. Interim results were based on 95 COVID-19 cases, 90 of which were reported in the placebo group and 5 in the vaccine group. 11 COVID-19 cases were severe, all of which occurred in the placebo group. Adverse events such as fatigue, injection site pain, and myalgia tended to be mild or moderate and resolved quickly.

[Press release, not peer-reviewed]’s-COVID-19-Vaccine-Candidate-Meets-its-Primary-Efficacy-Endpoint-in-the-First-Interim-Analysis-of-the-Phase-3-COVE-Study